Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HX008 + niraparib + trastuzumab
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
HX008 + niraparib + trastuzumab is an investigational combination therapy comprising three agents: - **HX008** is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), developed as an immune checkpoint inhibitor. - **Niraparib** is a small molecule poly(ADP-ribose) polymerase (PARP) inhibitor that impairs DNA repair in cancer cells with homologous recombination deficiency. - **Trastuzumab** is a recombinant humanized IgG1 monoclonal antibody targeting the HER2 receptor. It inhibits HER2-mediated signaling and induces antibody-dependent cellular cytotoxicity. This combination aims to leverage immune checkpoint inhibition (HX008), DNA damage response impairment (niraparib), and targeted anti-HER2 activity (trastuzumab). The rationale for combining these agents includes potential synergistic effects in HER2-positive cancers by promoting synthetic lethality and enhancing antitumor immunity. Clinical trials are ongoing to evaluate safety and efficacy in metastatic HER2-positive breast cancer.
- Other names
- HX008 + niraparib + trastuzumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on HX008 + niraparib + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HX008 + niraparib + trastuzumab.